Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, Hannah, McCabe, Nuala, Lord, Christopher J., Tutt, Andrew N. J., Johnson, Damian A., Richardson, Tobias B., Santarosa, Manuela, Dillon, Krystyna J., Hickson, Ian, Knights, Charlotte, Martin, Niall M. B., Jackson, Stephen P., Smith, Graeme C. M., Ashworth, Alan·2005·Nature
DOI 10.1038/nature03445

Cited by (1,042)

Items 1,001–1,042 of 1,042

  1. Bladder cancer organoids as a functional system to model different disease stages and therapy response
    Martina Minoli, Thomas Cantore, Daniel Hanhart, Mirjam Kiener, Tarcisio Fedrizzi, Federico La Manna, Sofia Karkampouna, Panagiotis Chouvardas, Vera Genitsch, Antonio Rodríguez-Calero et al. · 2023 · Nature Communications
  2. MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant Melanomas
    Maertens, Ophélia, Kuzmickas, Ryan, Manchester, Haley E., Emerson, Chloe E., Gavin, Alessandra G., Guild, Caroline J., Wong, Terence C., De Raedt, Thomas, Bowman-Colin, Christian, Hatchi, Elodie et al. · 2019 · Cancer Discovery
  3. The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
    Peng, Yihan, Liao, Qingchao, Tan, Wei, Peng, Changmin, Hu, Zhaohua, Chen, Yali, Li, Zhuqing, Li, Jing, Zhen, Bei, Zhu, Wenge et al. · 2019 · Nature Communications
  4. Targeting DNA Replication Stress for Cancer Therapy
    Zhang, Jun, Dai, Qun, Park, Dongkyoo, Deng, Xingming · 2016 · Genes
  5. Patient-derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
    Scott, Clare L., Becker, Marc A., Haluska, Paul, Samimi, Goli · 2013 · Frontiers in Oncology
  6. Mismatch repair deficiency in ovarian cancer — Molecular characteristics and clinical implications
    Xiao, Xue, Melton, David W., Gourley, Charlie · 2014 · Gynecologic Oncology
  7. Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
    Aguirre, Andrew J., Hahn, William C. · 2018 · Cold Spring Harbor Perspectives in Medicine
  8. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
    Shaashua, Lee, Ben-Shmuel, Aviad, Pevsner-Fischer, Meirav, Friedman, Gil, Levi-Galibov, Oshrat, Nandakumar, Subhiksha, Barki, Debra, Nevo, Reinat, Brown, Lauren E., Zhang, Wenhan et al. · 2022 · Nature Communications
  9. Combination Strategies to Improve Targeted Radionuclide Therapy
    Chan, Tiffany G., O’Neill, Edward, Habjan, Christine, Cornelissen, Bart · 2020 · Journal of Nuclear Medicine
  10. An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development
    van Pel, Derek M., Barrett, Irene J., Shimizu, Yoko, Sajesh, Babu V., Guppy, Brent J., Pfeifer, Tom, McManus, Kirk J., Hieter, Philip · 2013 · PLoS Genetics
  11. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
    Mandal, Jayaprakash, Mandal, Prativa, Wang, Tian-Li, Shih, Ie-Ming · 2022 · Journal of Biomedical Science
  12. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
    Wang, Dong, Wang, Min, Jiang, Nan, Zhang, Yuan, Bian, Xing, Wang, Xiaoqing, Roberts, Thomas M., Zhao, Jean J., Liu, Pixu, Cheng, Hailing · 2016 · Oncotarget
  13. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients
    Hurley, Judith, Reis, Isildinha M., Rodgers, Steven E., Gomez-Fernandez, Carmen, Wright, Jean, Leone, Jose Pablo, Larrieu, Rene, Pegram, Mark D. · 2013 · Breast Cancer Research and Treatment
  14. The potential of organoids in urological cancer research
    Wang, Shangqian, Gao, Dong, Chen, Yu · 2017 · Nature Reviews Urology
  15. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells
    Schoonen, Pepijn M., Kok, Yannick P., Wierenga, Elles, Bakker, Bjorn, Foijer, Floris, Spierings, Diana C. J., van Vugt, Marcel A. T. M. · 2019 · Molecular Oncology
  16. Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway.
    Dar, Ashraf, Shibata, Etsuko, Dutta, Anindya · 2013 · Molecular and Cellular Biology
  17. Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
    Tan, Lun, Zhang, Jifa, Wang, Yuxi, Wang, Xiye, Wang, Yanyan, Zhang, Zhixiong, Shuai, Wen, Wang, Guan, Chen, Juncheng, Wang, Chengdi et al. · 2022 · Journal of Medicinal Chemistry
  18. Genome Sequencing during a Patient’s Journey through Cancer
    Nangalia, Jyoti, Campbell, Peter J. · 2019 · New England Journal of Medicine
  19. DNA repair mechanisms protect our genome from carcinogenesis
    Moraes, Maria Carolina Strano · 2012 · Frontiers in Bioscience
  20. NAD+ in COVID-19 and viral infections
    Zheng, Minyan, Schultz, Michael B., Sinclair, David A. · 2022 · Trends in Immunology
  21. Hereditary breast cancer: From molecular pathology to tailored therapies
    Tan, D S P, Marchiò, C, Reis-Filho, J S · 2008 · Journal of Clinical Pathology
  22. Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence
    Graziano, S, Johnston, R, Deng, O, Zhang, J, Gonzalo, S · 2016 · Oncogene
  23. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
    Lee, Jung-Min, Peer, Cody J., Yu, Minshu, Amable, Lauren, Gordon, Nicolas, Annunziata, Christina M., Houston, Nicole, Goey, Andrew K.L., Sissung, Tristan M., Parker, Bernard et al. · 2017 · Clinical Cancer Research
  24. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
    Abraham, Jean E., Pinilla, Karen, Dayimu, Alimu, Grybowicz, Louise, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M., Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N. et al. · 2024 · Nature
  25. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
    Lim, Joline, Tan, David S. P. · 2017 · Cancers
  26. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer
    Pothuri, B. · 2013 · Annals of Oncology
  27. Massively parallel assessment of human variants with base editor screens
    Hanna, Ruth E, Hegde, Mudra, Fagre, Christian R, DeWeirdt, Peter C, Sangree, Annabel K, Szegletes, Zsofia, Griffith, Audrey, Feeley, Marissa N, Sanson, Kendall R, Baidi, Yossef et al. · 2020
  28. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials
    Ruiz-Schutz, Viviane C., Gomes, Larissa M., Mariano, Rodrigo C., de Almeida, Daniel V.P., Pimenta, Juliana M., Dal Molin, Graziela Z., Kater, Fabio R., Yamamura, Rosely, Correa Neto, Nelson F., Maluf, Fernando C. et al. · 2019 · Critical Reviews in Oncology/Hematology
  29. Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomes
    Momtaz, Parisa, O’Connor, Catherine A., Chou, Joanne F., Capanu, Marinela, Park, Wungki, Bandlamudi, Chaitanya, Berger, Michael F., Kelsen, David P., Suehnholz, Sarah P., Chakravarty, Debyani et al. · 2021 · Cancer
  30. Androgen signaling uses a writer and a reader of ADP-ribosylation to regulate protein complex assembly
    Yang, Chun-Song, Jividen, Kasey, Kamata, Teddy, Dworak, Natalia, Oostdyk, Luke, Remlein, Bartlomiej, Pourfarjam, Yasin, Kim, In-Kwon, Du, Kang-Ping, Abbas, Tarek et al. · 2021 · Nature Communications
  31. Targeting DNA damage repair pathways in pancreas cancer
    Crowley, Fionnuala, Park, Wungki, O’Reilly, Eileen M. · 2021 · Cancer and Metastasis Reviews
  32. Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future
    Hu, Meng-Ling, Pan, Yi-Ru, Yong, Yuan-Yuan, Liu, Yi, Yu, Lu, Qin, Da-Lian, Qiao, Gan, Law, Betty Yuen-Kwan, Wu, Jian-Ming, Zhou, Xiao-Gang et al. · 2023 · Ageing Research Reviews
  33. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
    Huang, Jau-Ling, Chang, Yu-Tzu, Hong, Zhen-Yang, Lin, Chang-Shen · 2022 · International Journal of Molecular Sciences
  34. Leveraging microenvironmental synthetic lethalities to treat cancer
    Metcalf, Kevin J., Alazzeh, Alaa, Werb, Zena, Weaver, Valerie M. · 2021 · Journal of Clinical Investigation
  35. Synthetic Lethality in Ovarian Cancer
    Chandrasekaran, Akshaya, Elias, Kevin M. · 2021 · Molecular Cancer Therapeutics
  36. Prediction of Genetic Interactions Using Machine Learning and Network Properties
    Madhukar, Neel S., Elemento, Olivier, Pandey, Gaurav · 2015 · Frontiers in Bioengineering and Biotechnology
  37. Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
    Schadt, Eric E., Buchanan, Sean, Brennand, Kristen J., Merchant, Kalpana M. · 2014 · Frontiers in Pharmacology
  38. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
    Alhusaini, Abdullah, Cannon, Aoife, Maher, Stephen G., Reynolds, John V., Lynam-Lennon, Niamh · 2021 · Biomedicines
  39. Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors
    Sun, Linmao, Liu, Yufeng, Guo, Xinyu, Cui, Tianming, Wu, Chenghui, Tao, Jie, Cheng, Cheng, Chu, Qi, Ji, Changyong, Li, Xianying et al. · 2024 · Nature Communications
  40. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS
    Almeida, Gilberto S., Bawn, Carlo M., Galler, Martin, Wilson, Ian, Thomas, Huw D., Kyle, Suzanne, Curtin, Nicola J., Newell, David R., Maxwell, Ross J. · 2017 · NMR in Biomedicine
  41. Unscheduled MRE11 activity triggers cell death but not chromosome instability in polymerase eta-depleted cells subjected to UV irradiation
    Federico, María Belén, Siri, Sebastián Omar, Calzetta, Nicolás Luis, Paviolo, Natalia Soledad, de la Vega, María Belén, Martino, Julieta, Campana, María Carolina, Wiesmüller, Lisa, Gottifredi, Vanesa · 2020 · Oncogene
  42. Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
    Penson, Richard T, Ambrosio, Allison J, Whalen, Christin A, Krasner, Carolyn N, Konstantinopoulos, Panagiotis A, Bradley, Charles, Matulonis, Ursula A, Birrer, Michael J · 2023 · The Oncologist